Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Nafamostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 9,341Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Talphera to Host Q4 2024 Financial Results Call on March 31, 2025
    Talphera to Host Q4 2024 Financial Results Call on March 31, 2025

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-to-host-fourth-quarter-and-full-year-2024-financial-results-and-corporate-update-call-and-webcast-on-monday-march-31-2025-302412500.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    Daiichi Sankyo discontinues development of Nafamostat in Japan
    Daiichi Sankyo discontinues development of Nafamostat in Japan

    18 Jun 2021

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/18382/daiichi-sankyo-discontinues-development-of-nafamostat-in-japan-for-covid-19-treatment.html

    BIOSPECTRUM ASIA
    18 Jun 2021
    Share Share
    Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formu
    Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formu

    30 Mar 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=136431&sid=2

    PHARMABIZ
    30 Mar 2021
    Share Share
    Chong Kun Dang proceeds to phase 2 trial in Russia to treat COVID-19
    Chong Kun Dang proceeds to phase 2 trial in Russia to treat COVID-19

    01 Sep 2020

    // L. Jeong-yeo KOREAN HERALD

    http://www.koreaherald.com/view.php?ud=20200901000612

    L. Jeong-yeo KOREAN HERALD
    01 Sep 2020
    Share Share
    The University of Tokyo, RIKEN, Nichi-Iko & Daiichi Sankyo ink R&D on nafamostat
    The University of Tokyo, RIKEN, Nichi-Iko & Daiichi Sankyo ink R&D on nafamostat

    08 Jun 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=126694&sid=2

    PHARMABIZ
    08 Jun 2020
    Share Share
    Sun Pharma to trial Nafamostat for Covid-19 treatment
    Sun Pharma to trial Nafamostat for Covid-19 treatment

    01 Jun 2020

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/sun-pharma-nafamostat-trial/

    CLINICALTRIALSARENA
    01 Jun 2020
    Share Share